03 Profile
Vital Signsby Bridgehead
Hansard to 12 November 2026 · 31,484 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Rare diseases
Hubert Trübel: no photograph is held, so the academic plate is shown instead.
Academic
Hubert Trübel
Prof.; Managing Director of ReadOn Therapeutics, a DEBRA Research spinout
Oct 2026Nov 2026to date
1
Quoted in the press, across 1 topic since 29 Oct 2026
02 Quoted on · 1 of 29 topics
Hubert Trübel: key facts
- Kind of voice
- Academic
- Role
- Prof.; Managing Director of ReadOn Therapeutics, a DEBRA Research spinout
- Quoted on
- Rare diseases
- Press coverage
- Quoted in the press
- Most recently quoted
- 29 Oct 2026
04 On the record · press
What Hubert Trübel has said
By outlet · bar length shows relative volume
- pmlive.com
Where Hubert Trübel has been quoted
- DEBRA Research joins with Topadur to advance therapies for dystrophic epidermolysis bullosapmlive.com · 29 Oct 2026
How we found the articles that name Hubert Trübel: we searched news for these terms.
- rare disease
- rare conditions
- orphan drugs
- genetic disorder
- cystic fibrosis
- motor neurone disease
- muscular dystrophy
- Huntington
Also searched with “rare disease” in each of 8 national papers. Every term for Rare diseases
Verbatim
“People living with dystrophic EB face severe complications that extend far beyond chronic wounds. Through our investment in Topadur, we are supporting the development of locally acting therapies that target several interconnected aspects of the disease.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 13 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.